Refractory Hodgkin lymphoma responds to pentostatin (2′-deoxycoformycin)

Leukemia and Lymphoma

Volumn 47, Issue 2, 2006, Pages 373-375

  Braiteh, Fadi ^a   Ng, Chaan ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CD30 ANTIBODY; CELL ANTIBODY; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IFOSFAMIDE; MDX 060 01; ONDANSETRON; OPIATE; PENTOSTATIN; UNCLASSIFIED DRUG; VINBLASTINE;

ADULT; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CASE REPORT; DISEASE COURSE; DRUG RESPONSE; FATIGUE; HODGKIN DISEASE; HUMAN; LETTER; MALE; NAUSEA; NIGHT SWEAT; PRIORITY JOURNAL;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; HODGKIN DISEASE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEOPLASM STAGING; PENTOSTATIN; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; REMISSION INDUCTION; SENSITIVITY AND SPECIFICITY; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 30644461685     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500282019     Document Type: Letter

References (11)

1. Hasenclever, D and Diehl, V. (1998) A prognostic score for advanced Hodgkin's disease New England Journal of Medicine, 339, pp. 1506 - 1514.
2. Smith, R and Chen, Q and Hudson, M and Link, M and Kun, L and Weinstein, H and Billett, A and Marcus, K and Tarbell, N and Donaldson, S. (2003) Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy Journal of Clinical Oncology, 21, pp. 2026 - 2033.
3. Longo, D and Duffey, P and Young, R and Hubbard, S and Ihde, D and Glatstein, E and (1992) Conventional dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability of cure Journal of Clinical Oncology, 10, pp. 210 - 218.
4. Horning, S and Chao, N and Negrin, R and Hoppe, R and Long, G and Hu, W and (1997) High-dose therapy and autologous hematopoeitic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices Blood 89, pp. 801 - 813.
5. Seymour, J and Talpaz, M and Kurzrock, R. (1997) Response duration and recovery of CD4+lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up Leukemia, 11, pp. 42 - 47.
6. Kurzrock, R and Pilat, S and Duvic, M. (1999) Pentostatin therapy of T-cell lymphomas with cutaneous manifestations Journal of Clinical Oncology, 17, pp. 3117 - 3121.
7. Tsimberidou, A and Giles, F and Duvic, M and Fayad, L and Kurzrock, R. (2004) Phase II study of pentostatin in advanced T-cell lymphoid malignancies: Update of an M.D. Anderson Cancer Center series Cancer, 100, pp. 342 - 349.
8. Monfardini, S and Sorio, R and Cavalli, F and Cerny, T and Van Glabbeke, M and Kaye, S and Smyth, J. (1996) Pentostatin (2′-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: Phase II study of the EORTC Early Clinical Trials Group Oncology, 53, pp. 163 - 168.
9. Spiers, A and Ruckdeschel, J and Horton, J. (1984) Effectiveness of pentostatin (2′-deoxycoformycin) in refractory lymphoid neoplasms Scandinavian Journal of Haematology, 32, pp. 130 - 134.
10. Cummings, F and Kim, K and Neiman, R and Comis, R and Oken, M and Weitzman, S and Mann, R and O'Connell, M. (1991) Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease Journal of Clinical Oncology, 9, pp. 565 - 571.
11. Grever, M and Coleman, M and Gray, D and Malspeis, D and Balcerzak, S and Neidhart, J. (1984) Definition of safe, effective dosing regimen of 2′-deoxycoformycin with biochemical investigation Cancer Treatment Symposium, 2, pp. 43 - 48.